Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on BriaCell Therapeutics. The associated price target was lowered to $40.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emily Bodnar has given her Buy rating due to a combination of factors surrounding BriaCell Therapeutics’ recent developments and strategic moves. The company has been awarded a $2 million non-dilutive grant from the US National Cancer Institute, which will support the advancement of Bria-PROS+ into clinical stages for metastatic prostate cancer. This grant not only reflects the high unmet need in this area but also underscores the interest in BriaCell’s personalized off-the-shelf immunotherapy platform.
Additionally, BriaCell’s Phase 3 trial for Bria-IMT in combination with checkpoint inhibitors is progressing well, with new key sites like UCLA and Mayo Clinic added to the study, enhancing enrollment speed. The trial’s interim analysis, expected in 2026, could provide significant insights into the treatment’s efficacy, given its promising median overall survival results. Furthermore, the company’s recent $15 million equity raise and share consolidation have strengthened its financial position, leading to an adjusted price target of $40, up from $32, reflecting a decrease in shares outstanding and a positive outlook on future developments.